198 related articles for article (PubMed ID: 34088994)
1. Androgen deprivation therapy and cognitive decline-associations with brain connectomes, endocrine status, and risk genotypes.
Buskbjerg CR; Amidi A; Buus S; Gravholt CH; Hadi Hosseini SM; Zachariae R
Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):208-218. PubMed ID: 34088994
[TBL] [Abstract][Full Text] [Related]
2. Cognitive changes and brain connectomes, endocrine status, and risk genotypes in testicular cancer patients-A prospective controlled study.
Buskbjerg CR; Amidi A; Agerbaek M; Gravholt CH; Hosseini SH; Zachariae R
Cancer Med; 2021 Sep; 10(18):6249-6260. PubMed ID: 34390226
[TBL] [Abstract][Full Text] [Related]
3. Cognitive impairment and associations with structural brain networks, endocrine status, and risk genotypes in patients with newly diagnosed prostate cancer referred to androgen-deprivation therapy.
R Buskbjerg C; Zachariae R; Buus S; H Gravholt C; Haldbo-Classen L; Hosseini SMH; Amidi A
Cancer; 2021 May; 127(9):1495-1506. PubMed ID: 33351221
[TBL] [Abstract][Full Text] [Related]
4. The impact of common genetic variants in cognitive decline in the first seven years of Parkinson's disease: A longitudinal observational study.
Chung J; Ushakova A; Doitsidou M; Tzoulis C; Tysnes OB; Dalen I; Pedersen KF; Alves G; Maple-Grødem J
Neurosci Lett; 2021 Nov; 764():136243. PubMed ID: 34509566
[TBL] [Abstract][Full Text] [Related]
5. Cognitive impairment and associations with structural brain networks, endocrine status, and risk genotypes in newly orchiectomized testicular cancer patients.
Buskbjerg CR; Zachariae R; Agerbæk M; Gravholt CH; Haldbo-Classen L; Hosseini SMH; Amidi A
Brain Imaging Behav; 2022 Feb; 16(1):199-210. PubMed ID: 34392471
[TBL] [Abstract][Full Text] [Related]
6. The effects of androgen deprivation on working memory and quality of life in prostate cancer patients: The roles of hypothalamic connectivity.
Chaudhary S; Zhornitsky S; Roy A; Summers C; Ahles T; Li CR; Chao HH
Cancer Med; 2022 Sep; 11(18):3425-3436. PubMed ID: 35315585
[TBL] [Abstract][Full Text] [Related]
7. The impact of long-term androgen deprivation therapy on cognitive function and socioeconomic decision making in prostate cancer patients.
Holtfrerich SKC; Knipper S; Purwins J; Castens J; Beyer B; Schlomm T; Diekhof EK
Psychooncology; 2020 Aug; 29(8):1338-1346. PubMed ID: 32539186
[TBL] [Abstract][Full Text] [Related]
8. Effects of COMT, DRD2, BDNF, and APOE Genotypic Variation on Treatment Efficacy and Cognitive Side Effects of Electroconvulsive Therapy.
Bousman CA; Katalinic N; Martin DM; Smith DJ; Ingram A; Dowling N; Ng C; Loo CK
J ECT; 2015 Jun; 31(2):129-35. PubMed ID: 25148110
[TBL] [Abstract][Full Text] [Related]
9. Catechol-O-Methyltransferase Gene Polymorphisms and the Risk of Chemotherapy-Induced Prospective Memory Impairment in Breast Cancer Patients with Varying Tumor Hormonal Receptor Expression.
Li W; Zhao J; Ding K; Chao HH; Li CR; Cheng H; Shen L
Med Sci Monit; 2020 Sep; 26():e923567. PubMed ID: 32985495
[TBL] [Abstract][Full Text] [Related]
10. Genetic and vascular modifiers of age-sensitive cognitive skills: effects of COMT, BDNF, ApoE, and hypertension.
Raz N; Rodrigue KM; Kennedy KM; Land S
Neuropsychology; 2009 Jan; 23(1):105-116. PubMed ID: 19210038
[TBL] [Abstract][Full Text] [Related]
11. Ligand-gated ion channels as potential biomarkers for ADT-mediated cognitive decline in prostate cancer patients.
Verma S; Singh V; Nagampalli V; Ponsky LE; Li CR; Chao H; Gupta S
Mol Carcinog; 2024 Jun; 63(6):1051-1063. PubMed ID: 38482990
[TBL] [Abstract][Full Text] [Related]
12. Executive function performance and change in aging is predicted by apolipoprotein E, intensified by catechol-O-methyltransferase and brain-derived neurotrophic factor, and moderated by age and lifestyle.
Sapkota S; Bäckman L; Dixon RA
Neurobiol Aging; 2017 Apr; 52():81-89. PubMed ID: 28131014
[TBL] [Abstract][Full Text] [Related]
13. Androgen-deprivation therapy and cognitive decline in the NEON-PC prospective study during the COVID-19 pandemic.
Araújo N; Costa A; Lopes-Conceição L; Ferreira A; Carneiro F; Oliveira J; Braga I; Morais S; Pacheco-Figueiredo L; Ruano L; Cruz VT; Pereira S; Lunet N
ESMO Open; 2022 Apr; 7(2):100448. PubMed ID: 35344749
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor-1 is associated with regulation of the luteinizing hormone production in men receiving androgen deprivation therapy with gonadotropin-releasing hormone analogues for localized prostate cancer.
Hara N; Takizawa I; Isahaya E; Nishiyama T; Hoshii T; Ishizaki F; Takahashi K
Urol Oncol; 2012 Sep; 30(5):596-601. PubMed ID: 21458314
[TBL] [Abstract][Full Text] [Related]
15. Cognitive ability, intraindividual variability, and common genetic variants of catechol-O-methyltransferase and brain-derived neurotrophic factor: a longitudinal study in a population-based sample of older adults.
Das D; Tan X; Bielak AA; Cherbuin N; Easteal S; Anstey KJ
Psychol Aging; 2014 Jun; 29(2):393-403. PubMed ID: 24956006
[TBL] [Abstract][Full Text] [Related]
16. Different androgen deprivation therapies might have a differential impact on cognition - An analysis from a population-based study using time-dependent exposure model.
Hong JH; Huang CY; Chang CH; Muo CH; Jaw FS; Lu YC; Chung CJ
Cancer Epidemiol; 2020 Feb; 64():101657. PubMed ID: 31918180
[TBL] [Abstract][Full Text] [Related]
17. Cognitive decline in prostate cancer patients undergoing ADT: a potential role for exercise training.
Mundell NL; Daly RM; Macpherson H; Fraser SF
Endocr Relat Cancer; 2017 Apr; 24(4):R145-R155. PubMed ID: 28209634
[TBL] [Abstract][Full Text] [Related]
18. BDNF and COMT, but not APOE, alleles are associated with psychiatric symptoms in refractory epilepsy.
Doherty C; Hogue O; Floden DP; Altemus JB; Najm IM; Eng C; Busch RM
Epilepsy Behav; 2019 May; 94():131-136. PubMed ID: 30909076
[TBL] [Abstract][Full Text] [Related]
19. Cognitive functioning in men receiving androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis.
McGinty HL; Phillips KM; Jim HS; Cessna JM; Asvat Y; Cases MG; Small BJ; Jacobsen PB
Support Care Cancer; 2014 Aug; 22(8):2271-80. PubMed ID: 24859915
[TBL] [Abstract][Full Text] [Related]
20. APOE, MAPT, and COMT and Parkinson's Disease Susceptibility and Cognitive Symptom Progression.
Paul KC; Rausch R; Creek MM; Sinsheimer JS; Bronstein JM; Bordelon Y; Ritz B
J Parkinsons Dis; 2016 Apr; 6(2):349-59. PubMed ID: 27061069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
